close Video Marine veteran pushes for use of psychedelic-assisted therapies for PTSD Juliana Mercer, director of public policy for the nonprofit organization Healing Breakthrough in San Diego, discusses how treatment involving MDMA can improve veterans' mental health challenges. A panel of advisers to the U.S.
Food and Drug Administration will meet to discuss a therapy based on the psychedelic drug MDMA for patients with post-traumatic stress disorder. The meeting is the farthest that a drug based on MDMA has ever reached in the FDA regulatory process for approval, following decades of activism. In clinical trials in over 190 patients, those who received doses of MDMA in addition to therapy showed a significant reduction in PTSD scores compared to placebo.
A panel of advisers to the U.S. Food and Drug Administration will meet on Tuesday to discuss a therapy based on the psychedelic drug MDMA for patients with post-traumatic stress disorder (PTSD) .
The meeting by the agency's independent experts is the farthest that a drug based on MDMA, commonly known as ecstasy or molly, has ever reached in the FDA regulatory process for approval. It follows a decades-long push by advocates who say drugs like MDMA can treat mental health disorders and have therapeutic applications beyond their illicit use. MARINE VET TOUTS BENEFITS OF PSYCHEDELIC-ASSISTED PTSD DRUGS AS FDA CONSIDERS MDMA APPROVAL The treatment is a capsule form of MDMA made by the public-benefit corporation Lykos Therapeuti.
